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Abstract
RNA interference holds tremendous potential as a therapeutic approach, especially in the treatment of malignant
tumors. However, efficient and biocompatible delivery methods are needed for systemic delivery of small interfering
RNA (siRNA). To maintain a high level of growth, tumor cells scavenge high-density lipoprotein (HDL) particles by
overexpressing its receptor: scavenger receptor type B1 (SR-B1). In this study, we exploited this cellular character-
istic to achieve efficient siRNA delivery and established a novel formulation of siRNA by incorporating it into recon-
stituted HDL (rHDL) nanoparticles. Here, we demonstrate that rHDL nanoparticles facilitate highly efficient systemic
delivery of siRNA in vivo, mediated by the SR-B1. Moreover, in therapeutic proof-of-concept studies, these nanopar-
ticles were effective in silencing the expression of two proteins that are key to cancer growth and metastasis (signal
transducer and activator of transcription 3 and focal adhesion kinase) in orthotopic mouse models of ovarian and
colorectal cancer. These data indicate that an rHDL nanoparticle is a novel and highly efficient siRNA carrier, and
therefore, this novel technology could serve as the foundation for new cancer therapeutic approaches.
Neoplasia (2011) 13, 309–319
Introduction
RNA interference (RNAi) is being increasingly recognized as a po-
tentially highly effective therapeutic approach [1–3]. This concept is
rooted in the power of RNAi (e.g., small interfering RNA [siRNA])
to silence genes that are difficult to target with conventional approaches,
such as antibodies or small molecule inhibitors. Although specific
gene targeting by RNAi is indeed promising [4–6], efficient and bio-
compatible methods of in vivo siRNA delivery are needed to realize its
full therapeutic potential. Although several transmembrane delivery
methods have been reported using liposomes [7–9] or other nanopar-
ticles [10–12], their therapeutic applications can be limited because of
toxicities or other concerns. Therefore, new and more specific methods
are needed for systemic delivery of siRNA.
Lipoproteins, especially high-density lipoprotein (HDL), are essen-
tial components of the lipid transport system. HDL plays a pivotal
role in reverse cholesterol transport by promoting the return of excess
cholesterol from peripheral cells to the liver for elimination (biliary ex-
cretion or use in enterohepatic cycle) [13]. Endogenously, HDL par-
ticles are completely biodegradable, and they have not been reported
to elicit immunologic responses. In addition, because HDL particles
are known to escape the reticuloendothelial system, they exhibit longer
residence time in the circulation [14] than most drug formulations or
other lipoproteins. The core contents of the circulating HDL particles
are taken up through a receptor-mediated mechanism through scaven-
ger receptor class B type 1 (SR-B1) that is primarily expressed in the
liver [15,16] and most malignant cells [17]. On the basis of attractive
features such as small size, shielded hydrophobic core, and the possibil-
ity of receptor mediated uptake by the targeted tumor cells [18,19],
HDL nanoparticles are ideal drug carriers. Reconstituted HDL (rHDL)
is the synthetic form of the circulating human HDL lipoprotein. The
composition of rHDL nanoparticles includes phosphatidylcholine,
apolipoprotein A-1, cholesterol, and cholesteryl esters [20] (Figure 1A).
The rHDL nanoparticles are small with, an approximate diameter of
12 to 18 nm.
To develop targeted delivery approaches for siRNA [6,10,21], several
tumor cell receptors have been examined. The SR-B1 receptor is ex-
pressed mainly in the liver and, to a lesser extent, in the adrenal glands
or normal ovarian tissues [22–26]. However, SR-B1 expression in
malignant cells is quite prominent. Increased uptake of HDL results
in higher rates of tumor cell proliferation. For example, breast cancer
cells increase uptake of cholesterol esters by increasing SR-B1 expres-
sion [14]. Thus, given the role of SR-B1 in HDL homing to tumor
cells, we considered rHDL nanoparticles attractive for selective delivery
of therapeutic payloads.
Use of siRNA for therapeutic silencing is particularly attractive for
genes that are difficult to target with other approaches [27]. Signal
transducer and activator of transcription 3 [STAT3] is known to me-
diate normal cellular response to a variety of cytokines and growth fac-
tors [28,29]. Activation of STAT3 results in key processes involved in
malignant transformation and progression (e.g., cell proliferation, dif-
ferentiation, and survival) [30]. Although STAT3 is activated in many
solid tumors, it is known to be expressed in normal tissues and is
involved in many normal cellular processes [28,29]. Therefore, using
small molecule inhibitors or other nonspecific methods of targeting
STAT3 could result in many unwanted adverse effects, and this war-
rants a more selective approach to limit toxicity. Similarly, focal adhe-
sion kinase (FAK) is critical for tumor cell survival, migration, and
invasion [31–34]. In ovarian cancer patients, FAK overexpression is
linked to aggressive tumor features that contribute to poor overall sur-
vival [35]. For proof-of-concept, we demonstrate therapeutic efficacy
by targeting both STAT3 and FAK by using the rHDL nanoparticle
delivery method in ovarian and colorectal cancer models.
Materials and Methods
rHDL Nanoparticle Preparation and siRNA Incorporation
SiRNAwas incorporated into rHDL nanoparticles [36] and stored at
−20°C. Briefly, apolipoprotein A-I (Apo A-I), which is the major core
protein in the rHDL particle, was isolated and purified using a plasmid
vector for the production of protein [37]. Next, a mixture of lipids
(cholesterol [C]/cholesteryl oleate [CE]/egg yolk phosphatidylcholine
[PC], molar ratio of 1:5:1.3:115) was dried under a stream of nitrogen.
Five micrograms of siRNA was preincubated with 25 μg of oligolysine
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(mean MWt, 500-2000) at 30°C, for 30 minutes, and then added to
the lipid ingredients. The oligolysine/siRNA mixture was then com-
bined with lipids and dispersed in 60 μl of DMSO and 1.4 ml of
buffer (10 mM Tris, 0.1 M KCl, 1 mM EDTA pH 8.0). Sodium
cholate, 140 μl (100 mg/ml stock in 0.15 M NaCl, 0.003 M KCl,
0.15 M KH2PO4, pH 7.4 [designated as PBS]) was added to produce
a final PC-to-cholate molar ratio of ∼1:1.6. Apo A-I (12.7 mg/ml) in
0.4 ml of PBS was added to the mixture, and the final volume was
adjusted to 2 ml with PBS. The lipid-protein-cholate mixture was
then incubated for 12 hours at 4°C, followed by dialysis against 2 L of
PBS, for 2 days, with three buffer changes. Stability of the formulation
was determined using RiboGreen assay (Quant-iT Ribogreen Kit, Cat
no. R11490; Invitrogen, Carlsbad, CA) in subsequent gel exclusion chro-
matography. The rHDL/targeted siRNA solution was then diluted in
0.9% normal saline to a concentration of 0.2 mg/kg siRNA/0.2 ml of
rHDL solution. In addition, zeta potential of the rHDL nanoparticle
was measured using Zeta Plus (Brookhaven Instrument Co, Novato,
CA). Briefly, 1 ml of nanoparticles was added to a 1-ml cuvette for the
assessment of zeta potential of nanoparticles.
Transmission Electron Microscopy
After dialysis against 0.125 M ammonium acetate, 2.6 mM ammo-
nium carbonate, 0.26 mM EDTA, pH 7.4, the rHDL samples were
negatively stained with 2% sodium phosphotungstate, pH 7.2, and
placed on Formvar/carbon–coated 200-mesh nickel grid support films
(Ted Pella, Inc, Redding, CA). The particles were visualized (magnifi-
cation of 50,000) using a Zeiss 910 transmission electron microscope
(Carl Zeiss MicroImaging, LLC, Thornwood, NY). The photographs
obtained were enhanced, and the particle diameter was determined with
Adobe Imageready CS2 software (Adobe Systems, Inc, San Jose, CA).
Cell Lines and Culture Conditions
The derivation and source of human epithelial ovarian cancer cell lines
HeyA8, SKOV3ip1, and HeyA8-MDR have been reported previously
Figure 1. Characterization of rHDL nanoparticles. (A) Illustrations of rHDL nanoparticle composition. (B) Electron micrograph of rHDL
nanoparticles containing control siRNA. (C) Expression of SR-B1 in human epithelial ovarian cancer (IHC). (D) mRNA expression of SR-B1
in ovarian and colorectal cancer cell lines.
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[7–9,38]. Human colorectal cancer cell line (HCT116) was a generous
gift from Dr Lee Ellis (University of Texas MD Anderson Cancer Cen-
ter, Houston, TX). All cell lines used in this study were authenticated by
the characterized cell line core at the University of Texas MD Anderson
Cancer Center. Briefly, the HeyA8 and SKOV3ip1 cells were main-
tained in RPMI 1640 supplemented with 15% fetal bovine serum
(FBS) and 0.1% gentamicin sulfate (Gemini Bio-Products, Woodland,
CA). HeyA8-MDR cells were maintained in RPMI 1640 supplemented
with 15% FBS, 300 ng/ml paclitaxel (Abraxis BioScience, Los Angeles,
CA), and 0.1% gentamicin sulfate. HCT116 cells were kept in culture
using Dulbecco modified Eagle medium supplemented with 10% FBS
and 0.1% gentamicin sulfate. All cells were kept in 5% CO2/95% air
at 37°C [39].
In Vitro Gene Silencing
STAT3 (target sequence 5′-GCCUCUCUGCA GAAUUCAA-3′),
FAK (target sequence 5′CCACCUGGGCCAGUAUUAU-3′), and a
nontargeted control sequence (target sequence 5′-UUCUCCGAAC-
GUGUCACGU-3′) were purchased from Sigma-Aldrich Corpora-
tion (Woodland, TX), and RNAiFect transfection reagent was used
(Qiagen, Valencia, CA) as per the manufacturer’s recommendations.
Briefly, SKOV3ip1 and HeyA8-MDR ovarian cancer cells were trans-
fected with 1.33 μg of specific siRNA/well in six-well plates in tripli-
cates, at 70% confluence. Transfection was performed using the 1:3.75
of siRNA and transfection reagent, respectively, in serum-free medium
for 6 hours with the following treatment groups: control siRNA and
STAT3 siRNA.
RNA Extraction and Complementary DNA Preparation
Cells were homogenized with Trizol (Invitrogen, Carlsbad, CA).
RNA was extracted (chloroform), precipitated (isopropanol), and puri-
fied (75% ethanol). cDNA was generated with 2.0 μg of high-quality
RNA using SuperScript-II reverse transcriptase kit (Invitrogen) [40].
Microarray Analysis
cDNA microarray was performed using the Illumina platform
(Illumina Inc, San Diego, CA) on SKOV3 cells that were treated in
10-cm cell culture plates with either STAT3 (8.0 μg) or control siRNA
(8.0 μg) in triplicate using RNAiFect transfection reagent (Qiagen) as
per the manufacturer’s recommendations. STAT3 gene silencing was
confirmed at the protein level using Western blot before the micro-
array analysis. Gene expression data from microarray analysis were
then loaded into the IPA Ingenuity pathway database, and differen-
tially expressed genes related to apoptosis were selected for validation.
Polymerase Chain Reaction Assay
Reverse transcription–polymerase chain reaction (RT-PCR) was pre-
formed using cDNA from normal human organs and cancer cell lines.
cDNA from human liver was used as a positive control for SR-B1 ex-
pression. Quantitative real-time PCR was performed in Applied Biosys-
tems 9500 series using conditions that have been previously described
[41] using SYBR Green Master Mix (Applied Biosystems, Foster City,
CA) in triplicate. β-Actin was used as an endogenous control. Mean
fold change is reported.
Western Blot Analysis
Cell lysates were prepared with modified radioimmune precipitation
lysis buffer [42]. Proteins were separated on 8% SDS-PAGE and trans-
ferred to nitrocellulose membrane (Bio-Rad Laboratories, Philadelphia,
PA), followed by incubation with STAT3 (1:2500) or FAK (1:5000)
antibodies (BD Biosciences, San Diego, CA) overnight at 4°C. Primary
antibody was detected using antimouse immunoglobulin G (GE
Healthcare, Buckinghamshire, England, UK) and developed with a
chemiluminescence detection kit (Perkin-Elmer, Covina, CA). β-Actin
(1:2000; Sigma) or vinculin (1:3000; Cell Signaling Technology, Inc,
Danvers, MA) confirmed equal loading.
Apoptosis Assay in Ovarian Cancer Cell
Twenty-four hours after treatment with control siRNA or STAT3
siRNA, ovarian cancer cells (SKOV3ip1 and HeyA8-MDR) cells were
treated with docetaxel (1 or 500 nM, respectively) for 72 hours (trip-
licate), washed, and incubated with 5 μl of Annexin V/PE and 7AAD
antibodies (BD Pharmingen, San Diego, CA) for 30 minutes. Flow
cytometry was then performed to analyze the samples as previously
described [43].
Immunohistochemistry
Fresh-frozen (OCT) sections were stained for CD31 (1:800 dilution;
Pharmingen) [7,44], and Ki-67 staining was performed on 5-μm-thick
formalin-fixed paraffin-embedded specimens [8]. To quantify micro-
vessel density (MVD), cell proliferation index (Ki-67), and cleaved
caspase-3, five random 0.159-mm2 fields were studied at 100× magni-
fication for each tumor, and microvessel density percent Ki-67 and
percent cleaved caspase-3–positive cells were counted [9]. SR-B1 ex-
pression in human epithelial ovarian tumors (n = 50) was determined
[38] using paraffin-embedded human ovarian cancer specimens from
the University of Texas MD Anderson Cancer Center’s tumor bank
after institutional review board approval. High versus low expression
was determined by a gynecologic pathologist using the following pro-
cedures: intensity was scored from 1 to 3, and distribution was scored
from 1 to 4. The product of the two values was used to determine the
extent of the expression, and a score greater than 4 was considered a
high expression.
TUNEL Staining
Fresh-frozen sections of tumor tissues from therapy experiments
(SKOV3ip1 model) were stained by terminal deoxynucleotidyl
transferase–mediated deoxyuridine triphosphate nick-end labeling
(TUNEL; green; Promega, Madison, WI) [38] and counterstained
with Hoechst 1:10,000 [44]. An apoptotic body was represented
by green fluorescence. To quantify apoptotic cells, TUNEL-positive
cells were calculated in 10 random fields at 200× from five separate
slides per group. Average values are presented.
Selective Delivery of siRNA
Female nude mice bearing SKOV3ip1 tumors were injected intrave-
nously (intravenously [IV] through the tail vein) or intraperitoneally
(IP) with 0.2 mg/kg of fluorescently tagged (Alexa555) control siRNA
(Sigma-Aldrich) or untagged control siRNA (n = 3 per group). Forty-
eight hours later, mice were killed, and tumors and organs (brain, heart,
lung, liver, kidney, and spleen) were collected and frozen in OCT.
Fluorescence Staining
Fresh-frozen tumor tissues from orthotopic ovarian cancer models
(SKOV3ip1) were fixed in acetone, washed with PBS, and counter-
stained with Hoechst (1:10,000). Fluorescence microscopy was used
to analyze slides at 400×. Ten high-power fields were analyzed per
slide, and a mean is reported.
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Orthotopic Ovarian Cancer Models
Female nude mice (10-12 weeks old) were obtained from the US
National Cancer Institute. All experiments were approved by the
Institutional Animal Care and Use Committee of the MD Anderson
Cancer Center.
FAK Targeting In Vivo
For FAK targeting experiments (SKOV3ip1 model), treatment was
given in the following groups (n = 10 per group): 1) empty rHDL
nanoparticles, 2) control siRNA/rHDL, 3) FAK siRNA/rHDL, 4)
control siRNA + docetaxel, and 5) FAK siRNA/rHDL + docetaxel.
STAT3 Targeting In Vivo
For STAT3 silencing experiments, treatment was given according to
the following groups (n = 10 per group): 1) control siRNA/rHDL, 2)
control siRNA/rHDL + docetaxel, 3) STAT3 siRNA/rHDL, and 4)
STAT3 siRNA/rHDL plus docetaxel. Tumor cells from appropriate
ovarian cancer mouse models (HeyA8, 2.5 × 105; SKOV3ip1 and
HeyA8-MDR, 1.0 × 106) were injected intraperitoneally into mice
on day 0. Mice were randomized and treatment was started on day 7.
About 3 (HeyA8) or 5 weeks (SKOV3ip1 and HEYA8-MDR) later,
mice were subjected to necropsy, and tumors were harvested.
Colorectal Cancer Metastasis Model
For colorectal cancer metastasis model, HCT116 cells (1.0 × 106)
were injected into the spleen (n = 10 per treatment group) of female
nude mice. Two weeks later, treatment with oxaliplatin was started as
previously described [39], according to the groups shown in Figure 2C .
After 4 weeks, mice were killed, and tumors were harvested.
In Vivo Dose-Finding Experiment
An effective dose required to silence STAT3 or FAK genes in vivo
was determined by injecting doses ranging from 0.1 to 0.2 mg/kg of
STAT3 siRNA/rHDL or FAK siRNA/rHDL in SKOV3ip1 tumor-
bearing mice. Mice were subjected to necropsy on day 2, 4, or 6.
Tumors were harvested, and protein expression was determined using
Western blot analysis as described above.
Statistical Analysis
Continuous variables were compared using the Student’s t test
(between two groups) or analysis of variance (for all groups) if nor-
mally distributed. In nonparametric values, continuous variables were
compared with the use of the Mann-Whitney rank sum test or Kruskal-
Wallis test (for all groups). For in vivo rHDL therapy studies, 10 mice
per treatment group were randomly assigned. Thus, our sample size
provided 80% power to detect a 50% reduction in tumor weight at
5% level of statistical significance. We performed all statistical tests
using SPSS (SPSS, Inc, Chicago, IL) and GraphPad Prism 5 software
(GraphPad software, Inc, La Jolla, CA). We considered P < .05 to be
significant. All statistical tests performed in this study were two-tailed.
Results
Preparation of RNAi Containing rHDL Nanoparticles
Because RNAi molecules are highly ionic, especially because of
the presence of the negatively charged phosphate groups, we devised
a novel formulation to incorporate siRNA into rHDL. Oligolysine
peptides containing approximately 40 lysine residues provided the
neutralizing component that allowed efficient incorporation (>90%)
of siRNAmolecules into rHDL. After siRNA incorporation, the rHDL
nanoparticles have a diameter of ∼10 nm (Figure 1, A and B) and pos-
sess a neutral charge (ζ potential, −3.2 mV). The rHDL nanoparticles
were shown to have a robust payload carrying capacity (up to 4 mg of
siRNA/ml). In addition, the siRNA containing nanoparticles were found
to be exceptionally stable because no loss of siRNAwas noted from rHDL
complexes on 2 weeks of storage and redialysis of the samples.
SR-B1 Expression in Cancer Cells
Before testing the efficacy of rHDL as a delivery method for siRNA,
we first analyzed multiple cell lines and human tumors for presence
of the SR-B1 receptor. Among 50 human ovarian epithelial cancers,
96% of tumors expressed SR-B1 receptor (Figure 1C). In addition, we
determined SR-B1 expression in normal human organs and in multiple
breast, colorectal, pancreatic, and ovarian cancer cell lines using RT-PCR
(Figure W1), and several cell lines were also examined with quantitative
real-time PCR (Figure 1D). All of the cancer cell lines tested demon-
strated high levels of SR-B1 expression. Among the normal tissues,
only liver had high SR-B1 expression, whereas others had minimal to
no expression.
Selective Delivery of rHDL Nanoparticles In Vivo
Given the high expression of SR-B1 in tumors compared with nor-
mal tissues [17], we next examined the efficiency of in vivo siRNA
delivery using rHDL nanoparticles. Fluorescently tagged (Alexa555)
siRNA was incorporated into rHDL nanoparticles and injected IV
or IP (Figure 2A). After a single injection, the siRNA was distributed
evenly to ∼80% of a given tumor. We further asked whether the rHDL
particle delivery was receptor mediated. To address this question, we
first analyzed organs from mice that were treated with the Alexa555-
tagged siRNA/rHDL (Figure W2). Highest uptake of rHDL nano-
particles was noted in the liver, whereas minimal to no delivery was
noted in brain, heart, lung, kidney, or spleen. In addition, there were
no significant differences in tumor uptake of rHDL particles after
intraperitoneal versus intravenous administration of rHDL/Alexa555
(Figure W2).
Before conducting long-term therapy experiments with this ap-
proach, we next examined the efficacy of STAT3 siRNA incorporated
into rHDL nanoparticles (siRNA/rHDL) for gene silencing in vivo.
STAT3 siRNA efficacy was first tested in vitro (FigureW3A) in SKOV3
cells where 5 μg of STAT3 siRNA resulted in greater than 80% reduc-
tion in STAT3 protein expression compared with control siRNA. Next,
to determine an effective dose required to silence STAT3 in vivo, we
injected doses ranging from 0.1 to 0.2 mg/kg of STAT3 siRNA/rHDL
in SKOV3ip1 tumor bearing mice. On day 4, after a single injection
of 0.2 mg/kg of siRNA, we found 88% reduction in STAT3 protein
levels (Figure W3B), with some return of expression by day 6. On the
basis of this experiment, we used the 0.2-mg/kg dose for all subsequent
studies. Similar results were noted (FigureW3C) with targeting another
critical gene for cancer growth and metastasis, FAK [7]. FAK siRNA/
rHDL resulted in 87% reduction in FAK levels on day 4 after a single
injection of FAK siRNA incorporated into rHDL nanoparticles in nude
mice bearing SKOV3ip1 tumors.
Effect of STAT3 or FAK Gene Silencing on Tumor Growth
and Metastasis
After successfully silencing STAT3 or FAK genes in vivo (FigureW3B
and C), we next tested the therapeutic efficacy of this approach with
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or without docetaxel chemotherapy. We first targeted STAT3 using
STAT3 siRNA/rHDL (Figure 2B). Mice were treated with either STAT3
siRNA/rHDL alone or in combination with docetaxel using three well-
characterized orthotopic mouse models of ovarian cancer. In the HeyA8
model, STAT3 siRNA/rHDL or docetaxel monotherapy reduced tumor
weight by 62% (P < .05, both). Combination treatment with STAT3
siRNA/rHDL and docetaxel resulted in the greatest reduction in tumor
weight (by 92%, P < .05) compared with controls. Similar results were
noted in the SKOV3ip1 model (Figure 2B). In addition, both HeyA8
and SKOV3ip1 ovarian cancer models demonstrated sizeable reductions
in the number of tumor nodules when mice were treated with STAT3
siRNA/rHDL with and without docetaxel therapy (Figure W4A).
Given that STAT3 is known to play a role in chemoresistance [45–
48], we also performed experiments in the taxane-resistant HeyA8-
MDR model (Figure 2B). As expected, docetaxel had no significant
effect on tumor growth. STAT3 siRNA/rHDL monotherapy resulted
in 76% reduction in tumor growth (P < .01). Combination of docetaxel
with STAT3 siRNA/rHDL resulted in even greater reduction in tumor
growth (by 91%, P < .001, compared with control and by 89%,
P < .001, compared with docetaxel). Similar effects were seen on number
Figure 2. Systemic delivery of siRNA using rHDL nanoparticles. (A) Uptake of Alexa555-labeled siRNA/rHDL in SKOV3ip1 tumors. A single IV
or IP injection of 0.2 mg/kg of Alexa555 labeled or 0.2 mg/kg of IV and IP injection of untagged siRNA/rHDL was administered in mice
bearing SKOV3ip1 tumors, and 48 hours later, tumors were harvested and counterstained with Hoechst (blue), and siRNA (red) uptake
was assessed with fluorescence microscopy. The H&E image shows tumor histologic diagnosis. The adjacent graph shows percent
Alexa555-positive cells. (B) In vivo efficacy of STAT3 siRNA/rHDL in chemosensitive (HeyA8 and SKOV3ip1) and chemoresistant (HeyA8-
MDR) mouse models of ovarian carcinoma. *P < .05 compared with controls. **P < .05 compared with controls as well as docetaxel
alone. (C) In vivo efficacy of STAT3 siRNA/rHDL in colorectal cancer model of liver metastases (HCT116). *P < .05 compared with control
siRNA/rHDL, **P< .05 comparedwith STAT3 or oxaliplatin alone. In vivo efficacy of FAK siRNA/rHDL in the SKOV3ip1 ovarian cancermodel.
*P < .05 compared with controls. **P < .05 compared with controls as well as docetaxel alone. Error bars, SEM.
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of tumor nodules (Figure W4B). We also analyzed the frequency of
metastasis by location in animals in each treatment group (FigureW4B).
Compared with control and docetaxel monotherapy groups, STAT3
siRNA/rHDL alone or in combination with docetaxel resulted in a sub-
stantial reduction in upper abdominal and parenchymal liver metastasis.
Next, we examined the therapeutic effect of STAT3 gene silencing
in a well-characterized mouse model of metastatic colorectal cancer
(HCT116) [39] that has high baseline SR-B1 expression (Figure 2C ).
After tumor cell injection into the spleen, there is metastatic spread to
the liver in this model. STAT3 siRNA/rHDL treatment alone resulted
in 79% reduction in tumor weight (P < .01). For these experiments,
we used the commonly used cytotoxic, oxaliplatin, in combination with
STAT3 siRNA/rHDL. Oxaliplatin reduced tumor growth by 55%
(P < .01). The combination of oxaliplatin and STAT3 siRNA/rHDL
resulted in the most significant reduction in tumor weight (96%, P <
.01) and the number of metastatic lesions in the liver (86%, P < .01)
compared with controls. To assess the safety of rHDL nanoparticles,
we assessed several parameters in mice treated with rHDL nanoparticles
(FigureW5). Therewere no significant differences in animal bodyweight
or liver function tests (AST and ALT ratio) between different treatment
groups (Figure W5, A and B). Hematoxylin and eosin (H&E) staining
of multiple normal organs after therapy experiments revealed no signifi-
cant changes compared with the control group (Figure W5C).
To test the potential utility of rHDL nanoparticles against other tar-
gets, we carried out additional experiments with FAK siRNA/rHDL.
Here, we targeted FAK using FAK siRNA/rHDL in the SKOV3ip1
orthotopic model of ovarian carcinoma (Figure 2C ). FAK or docetaxel
monotherapy resulted in 62% and 74% reduction in tumor weight
(P < .01, both). The combination treatment resulted in the greatest
reduction in tumor weight (by 96%, P < .01) and the number of tumor
nodules (by 74%, P < .05). There were no significant differences in
tumor weights or number of tumor nodules between mice that were
treated with empty rHDL nanoparticles versus those treated with con-
trol siRNA/rHDL.
Effect of STAT3 Targeting on Tumor Microenvironment
To understand the biologic effects of STAT3/rHDL treatment, a
series of in vitro and in vivo experiments were carried out using both
chemosensitive (SKOV3ip1) and chemoresistant (HeyA8-MDR) ovar-
ian cancer models. In the SKOV3ip1 ovarian cancer model (Figure 3),
STAT3 gene silencing alone resulted in a 26% reduction in cell prolif-
eration (P < .05), whereas docetaxel inhibited tumor cell proliferation
by 30% (P < .05). Combination treatment with STAT3 siRNA/rHDL
and docetaxel reduced tumor cell proliferation by 48% (P < .05) com-
pared with controls (Figure 3). In the HeyA8-MDR ovarian cancer
model (Figure W6), where docetaxel treatment alone had no effect
on cell proliferation, STAT3 siRNA/rHDL monotherapy resulted in
19% reduction in proliferation. Combination of STAT3 siRNA/rHDL
and docetaxel resulted in most significant reduction (39%, P < .05)
compared with the control treatment (Figure W6).
To ascertain the effects of STAT3 silencing on tumor-associated
angiogenesis, we performed CD31 staining on fresh-frozen tumor
samples from all four treatment groups (Figures 3 and W6) and deter-
mined MVD. In the SKOV3ip1 model, STAT3 siRNA/rHDL or
docetaxel monotherapy resulted in 66% to 69% reduction (P < .05,
both) in MVD (Figure 3). The combination of STAT3 siRNA/rHDL
and docetaxel resulted in 88% reduction in MVD (P < .05) compared
Figure 3. Effect of rHDL-incorporated STAT3 siRNA on tumor microenvironment. Tissues harvested after STAT3 siRNA/rHDL therapy
were subjected to immunohistochemistry for markers of proliferation (Ki-67), angiogenesis (CD 31), and apoptosis (TUNEL). For the
TUNEL stain, five random fields per slide were examined with fluorescence microscopy, and the number of apoptotic bodies and nuclei
is reported as average percent apoptotic cells (200×). Error bars, SEM.
Neoplasia Vol. 13, No. 4, 2011 Targeted Delivery of Small Interfering RNA Shahzad et al. 315
with controls. Similarly, in theHeyA8-MDRmodel, docetaxel treatment
alone had no effect on MVD, but the combination of docetaxel with
STAT3 siRNA/rHDL resulted in a substantial reduction (Figure W6).
STAT3 is known to increase cell survival and inhibit apoptosis [45–
48]. Therefore, we also examined effects on tumor cell apoptosis using
TUNEL staining in the SKOV3ip1 ovarian cancer treatment model
(Figure 3) and cleaved caspase-3 staining in the HeyA8-MDR model
(Figure W6). In the SKOV3ip1 model, STAT3 gene silencing or
docetaxel treatment resulted in 8- to 12-fold increase in apoptosis
compared with controls (P < .05, both). Combination treatment with
STAT3 siRNA/rHDL and docetaxel resulted in a 30-fold increase in
tumor cell apoptosis compared with the control group (P < .05). In
addition, in the HeyA8-MDR model, docetaxel treatment alone had
no effect on apoptosis, but treatment with STAT3 siRNA/rHDL alone
or combination treatment with STAT3 siRNA/rHDL and docetaxel re-
sulted in substantial increase (by 61% and 76%, respectively, P < .05 for
both) in apoptotic cells (cleaved caspase-3–positive) compared with
control siRNA/rHDL treatment (Figure W6).
Tissue-Based Markers of STAT3 Silencing in Ovarian
Cancer Cells
To identify potential tissue-basedmarkers of response to STAT3 gene
silencing, we performed genomic analyses on control versus STAT3
siRNA-treated ovarian cancer cells (Figure 4, A and B). There were
460 genes that were differentially expressed between these two groups.
Given that the biologic data pointed toward apoptosis and impaired
cell survival as the dominant effects after STAT3 silencing, we focused
on genes in these pathways (Table W1). From this list, we validated
12 genes that were most significantly altered with STAT3 gene silenc-
ing (Figure 4C ) using quantitative real-time RT-PCR. The extent of
STAT3 gene silencing was consistent between the two modalities.
STAT3 silencing resulted in substantial decreases in key survival genes
Figure 4. Effect of STAT3 silencing on gene expression profile of ovarian cancer cells. (A) STAT3 silencing modulates gene expression of
apoptosis related genes. After STAT3 silencing with siRNA (in vitro), microarray analysis was performed. Heat map (A) represents the
over all gene expression changes. Analysis of apoptosis-related (B) genes are shown. (C) Validation of microarray. Apoptosis-related
genes that were differentially expressed between control siRNA and STAT3 siRNA treatment groups were validated with quantitative
real-time RT-PCR. Average fold change is presented. Error bars, SEM.
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that are known to regulate MAP kinase and AKT pathway (Figure 4C).
These genes may serve as important tissue-based markers of response to
STAT3-targeted therapy. Similar changes were noted in the HeyA8-
MDR model (data not shown).
Effects of In Vitro STAT3 Silencing on Apoptosis
To determine whether the effects of STAT3 gene silencing on
tumor cell apoptosis were direct, we examined the effects of STAT3
siRNA with or without docetaxel on ovarian cancer cell (SKOV3ip1
andHeyA8-MDR) viability (Figure 5). STAT3 silencing was confirmed
with Western blot analysis (Figure W3A). In SKOV3ip1 cells, STAT3
siRNA or docetaxel monotherapy resulted in increased apoptosis (by
3- and 5.2-fold, respectively, P < .05, both), whereas the combination
treatment resulted in 7.7-fold higher apoptosis compared with control
(P < .05). Compared with docetaxel treatment, the addition of STAT3
siRNA resulted in 41% greater apoptosis (P < .05), suggesting that the
observed in vivo apoptotic effects were indeed direct (Figure 5A). In
addition, docetaxel treatment in HeyA8-MDR cells (Figure 5B) did
not result in any significant apoptosis. However, exposure to docetaxel
after STAT3 silencing resulted in 175% increase (P < .05) in apoptosis
compared with controls and 98% higher apoptosis (P < .05) compared
with docetaxel treatment alone.
Discussion
The key findings of this study are that rHDL nanoparticles can effi-
ciently deliver siRNA in vivo to silence genes that are critical for cancer
growth and progression. This concept was illustrated by the highly
effective STAT3 or FAK gene silencing in multiple tumor models
through siRNA incorporated into rHDL nanoparticles. The biologic
effects were mediated by decreased tumor cell proliferation, reduction
in angiogenesis, and decreased cell survival.
Although RNA interference is a highly specific mode of gene silenc-
ing, its therapeutic application is currently limited due primarily to
difficulties in systemic in vivo delivery [49–51]. To overcome these
barriers, selective biocompatible delivery systems are needed. To date,
several nanoparticle systems have been used for potential therapeutic
interventions [11,12,52]; however, majority of these systems may result
in toxicities to normal tissues due to lack of tissue specificity and wide
body distribution [52,53]. Consequently, nonspecific delivery systems
may require higher doses to accomplish effective and sustained gene
silencing. Therefore, targeted delivery is highly desirable to overcome
the hurdles seen with other approaches [54].
There are many advantages of using rHDL as a delivery system for
siRNA. For example, cellular uptake of the rHDL core components is
considered to occur through a specific receptor (SR-B1), which allows
selective siRNA delivery. Our data show that SR-B1 receptor expres-
sion is increased in tumor cells compared with most normal tissues.
This differential expression may help in avoiding undesired side ef-
fects. In the current study, uptake of rHDL nanoparticles was largely
restricted to the tumor and liver. This pattern of uptake is entirely con-
sistent with the distribution of SR-B1 expression [24]. In addition, our
safety studies indicate that STAT3/rHDL uptake in the liver did not
result in any adverse effects in mice compared with the control siRNA
treatment group.
For proof-of-concept, we demonstrated successful therapeutic tar-
geting of two important genes for cancer growth and progression in
multiple preclinical models. STAT3 is a well-characterized transcription
factor that is involved in many key processes implicated in cancer pro-
gression and metastasis [55,56]. RNA interference is attractive as a ther-
apeutic strategy, especially against targets that are not easily “druggable”
by other methods. Although STAT3 is widely considered to be an im-
portant cancer promoter, conventional approaches are limited for its
targeting [57]. Therefore, siRNA delivery, as shown here, is an im-
portant approach for targeting STAT3 and other important facilitators
of malignant growth. The biologic effects of reduced angiogenesis,
secondary to STAT3 silencing in tumor cells, is supported by several
reports demonstrating that vascular endothelial growth factor expres-
sion is modulated by STAT3 activation [58]. Constitutively activated
STAT3 in tumor cells correlates with increased vascular endothelial
growth factor expression [59,60]. Consequently, targeting STAT3 for
Figure 5. Effect of STAT3 silencing on apoptosis. STAT3was silenced
using STAT3-specific siRNA in (A) SKOV3ip1 and (B) HeyA8-MDRcells
with and without docetaxel treatment, and apoptosis was assessed
using flow cytometry (annexin V). Average percent apoptosis (Annexin
V/PE–positive SKOV3 cells) and average percent apoptosis compared
with control (annexin V/PE–positive HeyA8-MDR cells) are reported.
Error bars, SEM.
Neoplasia Vol. 13, No. 4, 2011 Targeted Delivery of Small Interfering RNA Shahzad et al. 317
pharmacological intervention is now possible using the nanotechnology
approaches described here.
In addition, among other solid tumors, FAK has also been reported
to be over expressed in colorectal, breast, ovarian, thyroid, and pros-
tate carcinoma [35,61–64], and in patients with ovarian cancer, over-
expression of FAK is associated with aggressive tumor features resulting
in poor over all survival [35]. Systemic targeting of FAKwith liposomal
nanoparticles or small molecule inhibitors has shown reduction in tumor
growth andmetastasis [7,38], but such approaches are not tumor-specific
and could result in toxicities. FAK siRNA/rHDL treatment is highly
tumor specific and resulted in significant reduction in tumor growth
and metastasis without any obvious effects on other organs.
In summary, systemic siRNA delivery using rHDL nanoparticles
opens new horizons for treatment of human malignancies. This deliv-
ery method not only is highly efficient but also allows for selectivity
and biocompatibility. Thus, rHDL nanoparticles may have significant
implications for cancer management.
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Figure W1. Expression of SR-B1 mRNA in different human organs
and tumors using RT-PCR. Actin is used as a loading control.
Figure W2. Distribution of systemic delivery of fluorescent-labeled siRNA/rHDL. Alexa555-labeled control siRNA/rHDL or untagged siRNA/
rHDL was injected (IV or IP), and 48 hours later, organs were harvested. Fresh-frozen tissues were counterstained with Hoechst, and the
level of fluorescent-labeled siRNA (red) was assessed with fluorescent microscopy. Average fluorescence uptake is represented by the
graphs. *P < .05 compared with untagged siRNA/rHDL. H&E represents the organ morphology.
Figure W3. STAT3 and FAK silencing with siRNA/rHDL. (A) STAT3
siRNA treatment (in vitro) in SKOV3ip1 ovarian cancer cells. (B)
STAT3 siRNA/rHDL. (C) FAK siRNA/rHDL was injected in mice bear-
ing SKOV3ip1 ovarian tumors. Western blot analysis demonstrates
relative protein expression. Graphs represent mean expression in-
tensity measured with densitometry.
Figure W4. In vivo effect of STAT3 siRNA/rHDL with and without docetaxel therapy on tumor nodules in (A) HeyA8 and SKOV3 and (B)
HeyA8-MDR ovarian cancer models. The average number of tumor nodules is presented as a bar graph. Error bars, SEM. Three-dimensional
graph depicts the distribution of ovarian tumor metastasis in HeyA8-MDR (Taxol-resistant) ovarian cancer model.
Figure W5. Safety of rHDL nanoparticles. (A) Body weights. (B) Liver function tests (LFTs) measured at the end of therapy experiment
from all treatment groups are reported (for LFTs, AST and ALT ratio is presented). (C) Immunohistochemistry (IHC) performed on organs
after a long-term therapy experiment. Representative images of IHC from each treatment group are presented.
Figure W6. Effect of rHDL-incorporated STAT3 siRNA on tumor microenvironment. Tissues harvested after STAT3 siRNA/rHDL therapy
from HeyA8-MDR ovarian cancer mouse model were subjected to immunohistochemistry for markers of proliferation (Ki-67), angiogenesis
(CD 31), and apoptosis (cleaved caspase-3). For the analysis, five random fields per slide were examined with light microscopy and number
of average number of microvessels (MVD) or the number of cells positive (Ki-67 and cleaved caspase-3) and nuclei are reported as average
percent positive cells (200×). Error bars, SEM.
Table W1. Effect of Stat3 Silencing on Tumor Cell Apoptosis–Related Genes.
Gene Fold Change Gene Fold Change
ALOX5 1.43 KITLG 0.66
ATF6 0.44 NFKBIZ 0.65
BAX 1.49 NQO1 0.55
BCL6 0.72 NRP1 0.67
BEX2 1.46 PLAUR 0.72
CAV1 0.75 PMAIP1 0.69
CD24 0.73 PMEPA1 0.71
CDCP1 0.73 PRKRA 0.68
CTGF 0.62 RASA1 0.68
CYR61 0.68 RTN1 1.37
DKK1 0.72 SFRP1 0.55
DUSP1 0.74 SGK1 0.68
ETS2 0.56 SPARC 0.7
FGF2 0.68 SPP1 0.77
FOS 0.72 STAT3 0.23
HMOX1 1.79 TCF3 0.71
IGFBP3 0.45 TNFRSF11B 0.61
IL-6 0.61 TNFSF10 0.7
IL-1B 0.55 XBP1 0.74
Gene expression changes after STAT3 silencing. Forty-eight hours after STAT3 silencing in ovarian
cancer cells (SKOV3ip1), cDNAmicroarray analysis was performed. Average fold change in apoptosis-
related genes is reported.
